News
Resources
Blog
Sites
Megan Van Etten Megan Van Etten is senior director of public affairs at PhRMA. She is responsible for leading the association’s public affairs efforts on international issues, including trade, intellectual property and access to medicines. Prior to joining PhRMA, Megan was director of media and external communications at the U.S. Chamber of Commerce and communications director at the Beer Institute. She has also worked as a communications consultant for global public relations firms. When not at the office, Megan enjoys exploring new Washington, D.C. restaurants and traveling with her husband and friends.
Recent Posts
Partnerships are driving global COVID-19 treatment access
By Megan Van Etten | September 22, 2022
Through the constant efforts of U.S. innovators and their global partners, COVID-19 treatments have continued to be distributed to patients around the world — changing the pandemic’s treatment...
Read More
The dangers of expanding the TRIPS waiver
By Megan Van Etten | September 19, 2022
World Trade Organization (WTO) members, including the United States, are considering waiving commitments to honor certain intellectual property (IP) rights on COVID-19 treatments, following a harmful...
Read More
Patent policy changes proposed by USPTO and FDA would leave patients behind
By Megan Van Etten | July 22, 2022
Kathi Vidal, Director of the USPTO, and Robert M. Califf, FDA Commissioner, recently outlined several policy areas where they plan to collaborate on addressing drug pricing. PhRMA supports the goal...
Read More
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies
By Megan Van Etten | July 15, 2022
Member states of the World Trade Organization (WTO) recently agreed to a waiver of intellectual property (IP) protections for COVID-19 vaccines as part of the Trade-Related Aspects of Intellectual...
Read More
Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful
By Megan Van Etten | May 23, 2022
In two years, biopharmaceutical companies have gone from zero to 13 billion COVID-19 vaccine doses produced. They’ve worked across the industry and on every continent to meet the global demand for...
Read More
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
By Megan Van Etten | February 24, 2022
Biopharmaceutical companies are working across the industry and around the world to meet the global demand for COVID-19 vaccines. Companies have continued to ramp up their efforts to source needed...
Read More
Patients and innovators lose if the government pursues ‘march-in’
By Megan Van Etten | September 7, 2021
The Biden Administration this summer issued an executive order that seems to endorse the use of “march-in” – when the government seizes patent rights from an innovator to let competitors use that...
Read More
Driving further innovation is critical to global vaccine equity
By Megan Van Etten | August 24, 2021
The following is part of a series of Catalyst posts detailing each of the five strategies to advance COVID-19 global vaccine equity – which rely on and benefit from a strong innovation ecosystem.
Read More
Supporting country readiness to boost global vaccine access
By Megan Van Etten | August 12, 2021
The following is part of a series of posts detailing each of the five strategies to advance global COVID-19 vaccine equity – which rely on and benefit from a strong intellectual property ecosystem.
Read More
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
By Megan Van Etten | August 5, 2021
The following is part of a series of Catalyst posts detailing each of the five strategies to advance COVID-19 global vaccine equity – which rely on and benefit from a strong innovation ecosystem.
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
